NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem Profile by BTV
Business Television (BTV) visited NeoStem to speak with Dr. Robin Smith, Chairman and CEO, and Dr. Douglas Losordo,Chief Medical Officer,
News + EventsNeoStem to Present at the Swedish-American Life Science Summit 2014 August 20, 2014 - Learn MoreNeoStem Announces Second Quarter 2014 Financial Results and Provides Business Update August 7, 2014 -Learn MoreNeoStem Awarded 2014 Cell Therapeutics Technology Leadership Award from Frost & Sullivan July 14, 2014 -Learn More
On July 1st, approximately 14,456 shares of the Company’s common stock were purchased by employees of th.... Read More